WO2005063169A3 - Medikamentöse lipolyse von fettansammlungen - Google Patents

Medikamentöse lipolyse von fettansammlungen Download PDF

Info

Publication number
WO2005063169A3
WO2005063169A3 PCT/EP2004/014134 EP2004014134W WO2005063169A3 WO 2005063169 A3 WO2005063169 A3 WO 2005063169A3 EP 2004014134 W EP2004014134 W EP 2004014134W WO 2005063169 A3 WO2005063169 A3 WO 2005063169A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipolysis
medical
fat accumulations
fat
accumulations
Prior art date
Application number
PCT/EP2004/014134
Other languages
English (en)
French (fr)
Other versions
WO2005063169A2 (de
Inventor
Peter Boderke
Matthias Gossel
Walter Kamm
Karl-Heinz Nietsch
Rainer Pooth
Juergen Sandow
Joerg Hager
Gerhard Sattler
Original Assignee
Sanofi Aventis Deutschland
Peter Boderke
Matthias Gossel
Walter Kamm
Karl-Heinz Nietsch
Rainer Pooth
Juergen Sandow
Joerg Hager
Gerhard Sattler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland, Peter Boderke, Matthias Gossel, Walter Kamm, Karl-Heinz Nietsch, Rainer Pooth, Juergen Sandow, Joerg Hager, Gerhard Sattler filed Critical Sanofi Aventis Deutschland
Priority to EP04803773A priority Critical patent/EP1699490A2/de
Priority to BRPI0417932-3A priority patent/BRPI0417932A/pt
Priority to MXPA06006645A priority patent/MXPA06006645A/es
Priority to JP2006545984A priority patent/JP2007515439A/ja
Priority to CA002551474A priority patent/CA2551474A1/en
Priority to AU2004308072A priority patent/AU2004308072A1/en
Publication of WO2005063169A2 publication Critical patent/WO2005063169A2/de
Publication of WO2005063169A3 publication Critical patent/WO2005063169A3/de
Priority to IL176026A priority patent/IL176026A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Wässrige Zubereitungen, enthaltend mindestens ein Phospholipid und/oder mindestens eine Gallensäure und eine den Fettabbau unterstützende Komponente wie Riboflavin und Wasser eignen sich zur Herstellung von Arzneimitteln zur Entfernung von subkutanen Fettansammlungen und führen zur Regression der diätresistenten Fettpolster.
PCT/EP2004/014134 2003-12-22 2004-12-11 Medikamentöse lipolyse von fettansammlungen WO2005063169A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP04803773A EP1699490A2 (de) 2003-12-22 2004-12-11 Medikament se lipolyse von fettansammlungen
BRPI0417932-3A BRPI0417932A (pt) 2003-12-22 2004-12-11 lipólise medicamentosa de acúmulo de gordura
MXPA06006645A MXPA06006645A (es) 2003-12-22 2004-12-11 Lipolisis medica de acumulos de grasa.
JP2006545984A JP2007515439A (ja) 2003-12-22 2004-12-11 脂肪蓄積の医学的脂肪分解
CA002551474A CA2551474A1 (en) 2003-12-22 2004-12-11 Medical lipolysis of fat accumulations
AU2004308072A AU2004308072A1 (en) 2003-12-22 2004-12-11 Medical lipolysis of fat accumulations
IL176026A IL176026A0 (en) 2003-12-22 2006-05-30 Medical lipolysis of fat accumulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361067A DE10361067A1 (de) 2003-12-22 2003-12-22 Medikamentöse Lipolyse von Fettansammlungen
DE10361067.7 2003-12-22

Publications (2)

Publication Number Publication Date
WO2005063169A2 WO2005063169A2 (de) 2005-07-14
WO2005063169A3 true WO2005063169A3 (de) 2006-05-04

Family

ID=34673059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014134 WO2005063169A2 (de) 2003-12-22 2004-12-11 Medikamentöse lipolyse von fettansammlungen

Country Status (11)

Country Link
EP (1) EP1699490A2 (de)
JP (1) JP2007515439A (de)
KR (1) KR20060121238A (de)
CN (1) CN1897974A (de)
AU (1) AU2004308072A1 (de)
BR (1) BRPI0417932A (de)
CA (1) CA2551474A1 (de)
DE (1) DE10361067A1 (de)
IL (1) IL176026A0 (de)
MX (1) MXPA06006645A (de)
WO (1) WO2005063169A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846066B2 (en) 2004-05-19 2014-09-30 The Regents Of The University Of California Methods and related compositions for reduction of fat and skin tightening
US9186364B2 (en) 2009-03-03 2015-11-17 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2660172T3 (es) 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
PT1845938T (pt) * 2005-02-08 2019-07-11 Univ California Métodos e composições relacionadas para redução da gordura e para refirmar a pele
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
FR2937554B1 (fr) * 2008-10-27 2010-11-12 Yves Crassas Solutions salines aqueuses pour la destruction de tissus graisseux
CN102341109A (zh) * 2009-03-02 2012-02-01 多丽丝·赫克斯塞尔 医学美容脂肪萎缩
EP2471539B1 (de) 2009-08-25 2017-05-03 Medrx Co., Ltd. Transdermale zusammensetzung aus phosphatidylcholin und verfahren zu deren herstellung
DE102010028365A1 (de) 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
IN2014CN02188A (de) * 2011-08-23 2015-05-29 Kythera Biopharmaceuticals Inc
EP3119400B1 (de) * 2014-03-21 2021-06-02 Société des Produits Nestlé S.A. Maternale verabreichung von vitamin b2 zur verhinderung von erhöhter adipositas, übergewicht oder fettleibigkeit beim nachwuchs
MX2019002289A (es) * 2017-04-21 2019-09-26 Ami Pharm Co Ltd Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma.
KR102093872B1 (ko) * 2017-07-03 2020-03-27 진호성 지방제거용 주사제 조성물 및 이의 제조방법
JP6356329B2 (ja) * 2017-09-27 2018-07-11 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
CN110302082A (zh) * 2018-03-27 2019-10-08 上海同柏生物科技有限公司 用于减少身体脂肪沉积的技术及组合物制剂与应用
CN109674696A (zh) * 2018-03-27 2019-04-26 上海同柏生物科技有限公司 一种用于腹部脂肪降解技术及其制剂与应用
AU2021283320A1 (en) 2020-06-01 2022-12-08 Cosmed Pharmaceutical Co., Ltd. Beauty microneedle array
JP2022020578A (ja) * 2020-07-20 2022-02-01 コスメディ製薬株式会社 美容用外用剤及び化粧料
KR102513115B1 (ko) * 2020-12-18 2023-03-22 주식회사 레시텍 리토콜릭산을 포함하는 국소지방 감소용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10349979B4 (de) * 2003-10-24 2006-05-18 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale Lipolyse

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Lipostabil: The effect of phosphatidylcholine on subcutaneous fat", AESTHETIC SURGERY JOURNAL, vol. 23, October 2003 (2003-10-01), pages 413 - 417, XP002367101 *
"ROTE LISTE 2003", March 2003, ROTE LISTE SERVICE, FRANKFURT, XP002367103 *
HEXSEL D ET AL: "PHOSPHATIDYLCHOLINE IN THE TREATMENT OF LOCALIZED FAT", JOURNAL OF DRUGS IN DERMATOLOGY, STRATEGIC COMMUNICATION IN DERMATOLOGY, NEW YORK, NY, US, vol. 2, no. 5, October 2003 (2003-10-01), pages 511 - 518, XP009054358, ISSN: 1545-9616 *
RITTES P G: "The use of phosphatidylcholine for correction of localized fat deposits", AESTHETIC PLASTIC SURGERY, SPRINGER VERLAG, NEW YORK, NY, US, vol. 27, no. 4, July 2003 (2003-07-01), pages 315 - 318, XP002331642, ISSN: 0364-216X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846066B2 (en) 2004-05-19 2014-09-30 The Regents Of The University Of California Methods and related compositions for reduction of fat and skin tightening
US9186364B2 (en) 2009-03-03 2015-11-17 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof

Also Published As

Publication number Publication date
DE10361067A1 (de) 2005-07-14
WO2005063169A2 (de) 2005-07-14
CN1897974A (zh) 2007-01-17
CA2551474A1 (en) 2005-07-14
MXPA06006645A (es) 2006-08-31
EP1699490A2 (de) 2006-09-13
AU2004308072A1 (en) 2005-07-14
BRPI0417932A (pt) 2007-04-17
KR20060121238A (ko) 2006-11-28
IL176026A0 (en) 2006-10-05
JP2007515439A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2005063169A3 (de) Medikamentöse lipolyse von fettansammlungen
WO2005079797A3 (en) Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
WO2008058547A3 (en) Alpha-lactalbumin composition
EP2040713A4 (de) Gallensäurederivate als fxr-liganden zur prävention oder behandlung fxr-vermittelter erkrankungen oder leiden
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
WO2011027085A3 (fr) Principe actif issu de candida saitoana et utilisation cosmetique pour la detoxification des cellules de la peau
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
UA88634C2 (en) Quaternized quinuclidine esters
WO2008057252A3 (en) Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
WO2006089340A3 (en) Polynucleotide delivery to cardiac tissue
WO2005107711A3 (en) Method and composition for treating rhinitis
WO2004075815A3 (de) Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE452120T1 (de) Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
WO2005102309A3 (en) In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
WO2006039667A3 (en) Water-based delivery systems
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2009041691A1 (ja) 生体内留置物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480038625.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 176026

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004803773

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006645

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004308072

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006545984

Country of ref document: JP

Ref document number: 2234/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2551474

Country of ref document: CA

Ref document number: 1020067012553

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2004308072

Country of ref document: AU

Date of ref document: 20041211

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004308072

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004803773

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067012553

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0417932

Country of ref document: BR